Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Catastrophic antiphospholipid syndrome.

Joan T Merrill1, Ronald A Asherson

  • 1University of Oklahoma, USA. joan-merrill@omrf.ouhsc.edu

Nature Clinical Practice. Rheumatology
|August 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adiposity-Associated Monocyte Costimulatory Programming in Rheumatoid Arthritis Identified by Single-Cell Transcriptomics.

medRxiv : the preprint server for health sciences·2026
Same author

Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

"More guidelines than rules": reconsidering key gaps in the 2025 American College of Rheumatology treatment recommendations for systemic lupus erythematosus: comment on the article by Sammaritano et al.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Bias due to interval censored outcomes in a study of flare risk after hydroxychloroquine taper/cessation in systemic lupus erythematosus.

Journal of clinical epidemiology·2026
Same author

Comparative Performance of LFA-REAL, SLEDAI, and BILAG for Detecting Clinically Meaningful Changes in Lupus Activity.

Arthritis care & research·2026
Same author

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring.

Arthritis & rheumatology (Hoboken, N.J.)·2025

Catastrophic Antiphospholipid Syndrome (APS) is a severe condition causing rapid organ failure due to blood clots. Early diagnosis and treatment are crucial for improving patient outcomes and survival rates.

Area of Science:

  • Rheumatology
  • Hematology
  • Internal Medicine

Background:

  • Antiphospholipid syndrome (APS) is a thrombotic disorder linked to autoantibodies targeting phospholipids and associated proteins.
  • APS typically manifests as major arterial/venous occlusions or pregnancy complications.
  • Catastrophic Antiphospholipid Syndrome (CAPS), or Asherson's syndrome, is a severe APS variant characterized by rapid multiorgan failure from widespread small-vessel thrombosis.

Purpose of the Study:

  • To highlight the critical need for early diagnosis of CAPS.
  • To emphasize timely and effective treatment strategies for CAPS patients.
  • To underscore the ongoing efforts in understanding CAPS etiology to improve patient outcomes.

Main Methods:

  • Review of existing literature on Antiphospholipid Syndrome and its catastrophic variant.

Related Experiment Videos

  • Analysis of clinical characteristics and diagnostic criteria for CAPS.
  • Evaluation of current therapeutic approaches and their impact on prognosis.

    • Main Results:

    • CAPS presents with rapid, life-threatening multiorgan failure due to microvascular thrombosis.
    • Despite empiric treatments, CAPS carries a high mortality rate, with approximately 50% of patients dying from thrombotic events.
    • Survivors of the acute phase often experience long-term well-being, indicating the importance of managing the acute crisis.

    Conclusions:

    • Early recognition and prompt intervention are paramount for managing CAPS.
    • Further research into the underlying causes of CAPS is essential for developing more targeted and effective treatments.
    • Improving diagnostic and therapeutic strategies remains a priority to reduce the high mortality associated with this extreme condition.